Abstract:Introduction: Thrombocytopenia and autoimmune hemolytic anemia (AIHA) are extra-criteria manifestations of antiphospholipid syndrome (APS). They have a higher incidence in secondary cases, and there is little information on primary antiphospholipid syndrome (pAPS). Aim: To evaluate the clinical characteristics and profile of antibodies in pAPS with hematological activity. Material and methods: A retrospective study included patients with pAPS, diagnosed according to the Sapporo criteria with follow-up at third level of care in Mexico City from 1990 to 2021. Descriptive statistics were used, and chi-squared test, Mann-Whitney U test, and logistic regression were performed. Results: A total of 97 patients with pAPS were included; 73.2% (71) were women with a mean age of 33.9 + 11.5 years and a mean follow-up of 132 months (24-360). We found that 77% (75) presented thrombotic and 37% (36) obstetric manifestations. In 68% (66) of patients, hematological manifestations (non-exclusive groups) were found. Further, 63.9% had thrombocytopenia, the most common kind being severe, and a minority had AIHA in 13.4%. Table 1 describes the clinical manifestations. Patients with thrombocytopenia were younger, with 32 + 10.3 years vs 37 + 13 years ( p = 0.046). A total of 59.7% (37) had a triple marker. In comparison with patients without thrombocytopenia, 69.4% (43) presented positive lupus anticoagulant vs 48.6% ( p = 0.043) and OR 2.5 (CI 95% 1.06-6.1). An 83.9% (52) had positive IgG anticardiolipin vs 62.9% ( p = 0.019), OR 3.21 (CI 95% 1.19-8.63) with a higher titer of 19.4 vs 6.1 ( p = 0.017) and OR 1.01 (CI 95% 0.99-1.04). They had higher titers of antiβ2 glycoprotein-I IgM of 6.8 vs 5.2 ( p = 0.019) with OR 1.03 (CI 95% 0.99-1.06) and of antiphosphatidyl serine/prothrombin IgM of 52.8 vs 16.8 ( p = 0.004), OR 1.01 (CI 95% 1- 1.02). In patients with AHAI, anti-β2 glycoprotein-I IgM antibody titers of 7.1 vs 5.9 were identified, which were higher compared with those who did not present it ( p = 0.026). Those without hematological activity had more thrombosis ( p < 0.001). When comparing the groups with and without thrombosis, we observed that those with thrombosis had lower titers of antiβ2 glycoprotein-I IgM in 5.8 vs. 7.4, p = 0.036, OR 0.97 (CI 95% 0.94-1) and higher anti-phosphatidyl serine/prothrombin titers in 61.2 vs 12.1, p = 0.021 with OR 1.02 (CI 95% 1-1.04). A total of 76.3% (74) received anticoagulant and 24.7% (24) received antiplatelet. Immunosuppression was prescribed in 38.1% (37). Those with severe thrombocytopenia received: prednisone in 54.5% (18) of cases, methylprednisolone in 36.4% (12), rituximab in 3% (1), and splenectomy in 36.4% (12). In patients with AHAI, 84.6% (11) received immunosuppressants and 46.2% (6) underwent splenectomy. Conclusion: A higher incidence of hematological activity was identified in pAPS, mostly in young women. The most common kind was severe thrombocytopenia, as opposed to what was described in literature as mild to moderate. Differences were found regarding the titer and positivity of antibodies. With thrombocytopenia, there was a higher frequency of positive lupus anticoagulant, anticardiolipin IgG and antiβ2 glycoprotein-I IgM with higher titers. Patients had anti-phosphatidyl serine/prothrombin antibodies as an extended panel and a correlation with hematological activity was identified. Knowing the serology of pAPS is useful to identify in good time patients who may present severe hematological manifestations. No patient died of a hematologic complication; however splenectomy was required in some cases. To our knowledge this is one of the few studies that evaluate hematological manifestations in pAPS.

Ocular findings in asymptomatic patients with primary antiphospholipid syndrome

Ocular involvement in primary antiphospholipid syndrome: results of an extensive ophthalmological evaluation performed in the APS-Rio cohort

Ocular Posterior Segment Involvement in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome

Primary Antiphospholipid Syndrome: A Hidden Predisposing Factor for Retinal Vein Occlusion and Choroidal Neovascular Membrane Formation Among Young Population

[Ocular manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome]

Hematological Activity in Primary Antiphospholipid Syndrome: A Common Manifestation Outside the Classification Criteria

Phosphatidylserine-Dependent Anti-prothrombin Antibodies as a Key Predictor for Systemic Lupus Erythematosus in Patients with Primary Antiphospholipid Syndrome: A retrospective longitudinal cohort study

A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

Ocular Manifestations of Antiphospholipid Syndrome in Jordan

Systemic lupus erythematosus purtscher like retinopathy: Optical coherence tomography angiography assessment implications

Antiphospholipid Syndrome and Patent Foramen Ovale: A Case Report and Literature Review

Evaluation of Subclinical Retinal Disease in Patients Affected by Systemic Lupus Erythematosus with No Evidence of Ocular Involvement-An Optical Coherence Tomography Angiography Original Study

Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study

Retinal degeneration in autoimmune polyglandular syndrome type 1: a case series

Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus

The antiphospholipid syndrome - often overlooked cause of vascular occlusions?

Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

Optical coherence tomography angiography findings of systemic lupus erythematosus patients and the effect of neuropsychiatric involvement on it

Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome

A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome